Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 3/2011

01.09.2011 | General Gynecology

Anticholinergic therapy: do the patients take the pills prescribed?

verfasst von: Katharina Jundt, Kathrin Schreyer, Klaus Friese, Ursula Peschers

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate how many patients with overactive bladder still take their prescribed medication at least 12 months later and to find out the reasons for discontinuation of the therapy.

Methods

Two hundred and ten patients who had received a prescription for anticholinergic medication were contacted by telephone 12–46 months later.

Results

Out of 210 eligible patients 132 (63%) could be contacted and gave consent to participate in the study. 38% of them still took their medication after at least 12 months. 17% were continent or much improved, 13% a little improved, 8% were not improved, although still taking their medication. 62% did not take the original medication any more. 10% had never started with the medication, 42% took the medication for 3 months and 8% for 4–12 months. 25% had changed to another anticholinergic drug.

Conclusion

Anticholinergic therapy is often discontinued by patients and doctors. Patients with OAB therefore need counselling and follow-up in the long term to make sure that alternative treatment is offered if anticholinergic treatment does not work.
Literatur
1.
Zurück zum Zitat Abrams P, Cardozo L, Fall M, Griffiths DJ et al (2002) The standardisation of terminology of lower urinary tract function. Neurourol Urodynam 21:167–178CrossRef Abrams P, Cardozo L, Fall M, Griffiths DJ et al (2002) The standardisation of terminology of lower urinary tract function. Neurourol Urodynam 21:167–178CrossRef
2.
Zurück zum Zitat Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336PubMed Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336PubMed
3.
Zurück zum Zitat Roxburgh C, Cook J, Dublin N (2007) Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev CD003190 Roxburgh C, Cook J, Dublin N (2007) Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev CD003190
4.
Zurück zum Zitat Abrams P, Freeman RM, Anderstrom C, Mattiasson A (1998) Tolterodine, a new antimuscarinic agent; as effective but better tolerated than oxybutinin in patients with an overactive bladder. Br J Urol 81:801–810PubMed Abrams P, Freeman RM, Anderstrom C, Mattiasson A (1998) Tolterodine, a new antimuscarinic agent; as effective but better tolerated than oxybutinin in patients with an overactive bladder. Br J Urol 81:801–810PubMed
5.
Zurück zum Zitat Zinner NR, Tuttle J, Marks L (2005) Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutinin in patients with an overactive bladder. World J Urol 23:248–252PubMedCrossRef Zinner NR, Tuttle J, Marks L (2005) Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutinin in patients with an overactive bladder. World J Urol 23:248–252PubMedCrossRef
6.
Zurück zum Zitat Kelleher CJ, Cardozo L, Khullar V, Salvatore S (1997) A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988–993PubMedCrossRef Kelleher CJ, Cardozo L, Khullar V, Salvatore S (1997) A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988–993PubMedCrossRef
7.
Zurück zum Zitat Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z (2005) Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 11:S121–S129PubMed Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z (2005) Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 11:S121–S129PubMed
8.
Zurück zum Zitat Yu YF, Nichol MB, Yu AP, Ahn J (2005) Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health 8:495–505PubMedCrossRef Yu YF, Nichol MB, Yu AP, Ahn J (2005) Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health 8:495–505PubMedCrossRef
9.
Zurück zum Zitat Gopal M, Haynes K, Bellamy SL, Arya LA (2008) Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 112(6):1311–1318PubMedCrossRef Gopal M, Haynes K, Bellamy SL, Arya LA (2008) Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 112(6):1311–1318PubMedCrossRef
10.
Zurück zum Zitat Campbell UB, Stang P, Barron R (2008) Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence. Value Health 11:726–732PubMedCrossRef Campbell UB, Stang P, Barron R (2008) Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence. Value Health 11:726–732PubMedCrossRef
11.
Zurück zum Zitat Burgio KL (2004) Behavioral treatment options for urinary incontinence. Gastroenterology 126:S82–S89PubMedCrossRef Burgio KL (2004) Behavioral treatment options for urinary incontinence. Gastroenterology 126:S82–S89PubMedCrossRef
12.
Zurück zum Zitat Ward KL, Hilton P, Browning J (2000) (on behalf of the UK and Ireland TVT Trial Group). A randomized trial of colposuspension and tension-free vaginal tape (TVT) for primary genuine stress incontinence. Neurourol Urodynam 20:386–389 Ward KL, Hilton P, Browning J (2000) (on behalf of the UK and Ireland TVT Trial Group). A randomized trial of colposuspension and tension-free vaginal tape (TVT) for primary genuine stress incontinence. Neurourol Urodynam 20:386–389
13.
Zurück zum Zitat Reeves P, Irwin D, Kelleher C, Milsom I et al (2006) The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50:1050–1057PubMedCrossRef Reeves P, Irwin D, Kelleher C, Milsom I et al (2006) The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50:1050–1057PubMedCrossRef
14.
Zurück zum Zitat Zellner M, Madersbacher H, Palmtag H, Stöhrer M, Bödeker RH, P195 Study Group (2009) Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. Clin Ther 31(11):2519–2539 Zellner M, Madersbacher H, Palmtag H, Stöhrer M, Bödeker RH, P195 Study Group (2009) Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. Clin Ther 31(11):2519–2539
15.
Zurück zum Zitat Staskin D, Kay G, Tannenbaum C, Goldman HB, Bhashi K, Ling J, Oefelein MG (2010) Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 64(9):1294–1300 (Epub 2010 Jun 17) Staskin D, Kay G, Tannenbaum C, Goldman HB, Bhashi K, Ling J, Oefelein MG (2010) Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 64(9):1294–1300 (Epub 2010 Jun 17)
Metadaten
Titel
Anticholinergic therapy: do the patients take the pills prescribed?
verfasst von
Katharina Jundt
Kathrin Schreyer
Klaus Friese
Ursula Peschers
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 3/2011
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-010-1720-x

Weitere Artikel der Ausgabe 3/2011

Archives of Gynecology and Obstetrics 3/2011 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Menopausale Hormontherapie für Frauen über 65?

07.05.2024 Klimakterium und Menopause Nachrichten

In den USA erhalten nicht wenige Frauen auch noch im Alter über 65 eine menopausale Hormontherapie. Welche positiven und negativen gesundheitlichen Konsequenzen daraus möglicherweise resultieren, wurde anhand von Versicherungsdaten analysiert.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.